Biotech AssistantIndependent biopharma research
BIOTECH ASSISTANT / FIELD NOTES

FDA approves oral IL-23R peptide ICOTYDE for eligible patients with plaque psoriasis

Company / institutional announcement · Johnson & Johnson

Source published: · Event / reporting date: 2026-03-17

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗
Findings and limitationsIndustry implicationsRelated developments

What changed

FDA approved icotrokinra, marketed as ICOTYDE, on March 17; Johnson & Johnson announced the decision the following day. The once-daily oral IL-23 receptor antagonist is indicated for eligible adults and patients aged 12 or older weighing at least 40 kg with moderate-to-severe plaque psoriasis. The approval does not extend to ulcerative colitis or other investigational indications.

Why it may matter

Marks regulatory validation for a targeted oral peptide while requiring careful attention to indication, age, and weight restrictions.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oral cyclic peptides

Related updates

AJMC

Enlicitide reports address durability and baseline cardiovascular risk

Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.

Oral cyclic peptidesAsk AI ↗
Aurinia / SEC

Aurinia reports $232.4 million in nine-month LUPKYNIS net product sales

Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.

Oral cyclic peptidesAsk AI ↗
Acta Pharmaceutica Sinica B

New review maps evidence standards for orally active peptides

A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.

Oral cyclic peptidesAsk AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗